For the second year in a row, the average basic premium for a Medicare Part D plan will decline; a series of charts in The Wall Street Journal highlights what is driving US healthcare spending; taking a break from exercising can have metabolic consequences that linger for some people even after they return to their normal levels of exercise.
For the second year in a row, the average basic premium for a Medicare Part D plan will decline. According to CMS, Part D premiums are expected to fall from $33.59 in 2018 to $32.50 in 2019. In order to increase competition and drive down costs, CMS has introduced some changes, such as allowing for certain generic drugs to be substituted onto formularies more quickly and removing the requirement that certain Part D plans have to meaningfully differ from each other, which has made more plan options available and increased competition.
Healthcare costs in the United States are higher than other developed nations, but the cost isn’t high because Americans buy more healthcare. A series of charts in The Wall Street Journal highlighted what is driving US healthcare spending. Part of the issue is the opacity of the industry—patients don’t pay directly for services, instead the majority of health spending goes to paying for health insurance. The article highlighted the fact that consolidation also contributes to the overall increase in health costs.
Taking a break from exercising can have metabolic consequences that linger for some people even after they return to their normal levels of exercise, according to 2 new studies. The New York Times reported that the studies found that when volunteers reduced their daily step count and sat for more hours over the course of 2 weeks, their blood sugar levels rose and insulin resistance climbed. In addition, volunteers who started healthy began to lose muscle mass. Among volunteers who were older and already overweight, some had to be removed from the study because they “edged into full-blown type 2 diabetes.”
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
2 Commerce Drive
Cranbury, NJ 08512